Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Patritumab Deruxtecan Demonstrates Meaningful Activity in HR+/HER2– Advanced Breast Cancer

March 8th 2025

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

March 8th 2025

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

March 8th 2025

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Frontline Palbociclib Combo Improves Outcomes in Real-World HR+/HER2-Negative Breast Cancer Population From Disadvantaged Areas

March 8th 2025

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

March 7th 2025

Icro Meattini, MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer

March 7th 2025

PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC

March 7th 2025

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.

Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer

March 7th 2025

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer

March 7th 2025

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population

March 7th 2025

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

Real-World Findings Support the Safety of Frontline Ribociclib Plus ET for HR+/HER2-Negative Metastatic Breast Cancer

March 7th 2025

The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.

Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC

March 7th 2025

Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

March 5th 2025

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

March 4th 2025

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

March 4th 2025

Panelists discuss how to choose among therapeutic options when multiple molecular alterations are detected, identify patient populations better suited to specific therapies, and share their excitement about potential advances in the HR+/HER2– breast cancer space.

Impact of ADC Toxicities and Clinical Decision-Making for mBC

March 4th 2025

Panelists discuss adverse events associated with antibody-drug conjugates (ADCs) that impact clinical decision-making and share strategies for managing these adverse events.

Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm

March 3rd 2025

Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.

TNBC Awareness Day Emphasizes Progress in Treatment Strategies

March 3rd 2025

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.

The OncFive: Top Oncology Articles for the Week of 2/23

March 1st 2025

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs

February 26th 2025

Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.